Evidence map›Paper›PMID 38765021›Full record

ArticleBioinformatics and biology insights2024

Investigating the Antimicrobial Effects of a Novel Peptide Derived From Listeriolysin S on

Mojgan Sarabi Nobakht, Kaveh Bazyar, Mohammad Sadegh Ghalyanchi Langeroudi, Mandana Mirzaei, Mehdi Goudarzi, Ali Shivaee

Abstract read
In one paragraph

Article in Bioinformatics and biology insights, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mojgan Sarabi NobakhtDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Kaveh BazyarDepartment of Clinical Science, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Mohammad Sadegh Ghalyanchi LangeroudiDepartment of Clinical Science, Faculty of Veterinary Medicine, Islamic Azad University, Karaj, Iran.
Mandana MirzaeiDepartment of Microbiology, Faculty of Science, Islamic Azad University, Karaj, Iran.
Mehdi GoudarziDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-6720-9341
Ali ShivaeeDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: The emergence of antibiotic resistance is one of the most significant issues today. Modifying antimicrobial peptides (AMPs) can improve their effects. In this study, the active region of Listeriolysin S (LLS) as a peptidic toxin has been recognized, and its antibacterial properties have been evaluated by modifying that region. Methods: After extracting the sequence, the structure of LLS was predicted by PEP-FOLD3. AntiBP and AMPA servers identified its antimicrobial active site. It was modified by adding arginine residue to its 3- and N-terminal regions. Its antimicrobial properties on Findings: The results of AntiBP and AntiBP servers demonstrated that a region of 15 amino acids has the most antimicrobial properties (score = 1.696). After adding arginine to the chosen region, the physicochemical evaluation and antimicrobial properties revealed that the designed peptide is a stable AMP with a positive charge of 4, which is not toxic to human erythrocyte cells and has antigenic properties. The results of in vitro and colony counting indicated that at different hours, it caused a significant reduction in the count of Conclusions: Upcoming research implies that identifying and enhancing the active sites of natural peptides can help combat bacteria.

Indexed as

Antimicrobial peptidesE coliListeriolysin SL plantarumS aureus

Identifiers

PMID38765021
PMCPMC11100392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.